Adaptive Biotechnologies vs Immunocore
ADPT and IMCR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ADPT and IMCR compare
Adaptive Biotechnologies is the larger company, worth 3.2 times as much as Immunocore ($4.5B against $1.4B).
Adaptive Biotechnologies grew revenue faster over the last twelve months (50.1% versus 21.0% for Immunocore).
Immunocore keeps more of each dollar of sales as profit, with a net margin of −4.2% compared with −20.7% at Adaptive Biotechnologies.
Adaptive Biotechnologies scores higher on the StockData Score (12 against 7 for Immunocore), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ADPT | IMCR |
|---|---|---|
| Size and price | ||
| Market cap | $4.5B | $1.4B |
| Share price | $28.49 | $27.81 |
| Change, 1 year | 102% | −22.6% |
| Change, 5 years | 1.3% | −23.6% |
| Beta (5Y) | 0.51 | 0.19 |
| Employees | 624 | 524 |
| StockData Score | ||
| Total score | 12 (better) | 7 |
| Valuation score | 0 | 1 (better) |
| Growth score | 4 (better) | 2 |
| Performance score | 3 | 3 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 14.8× | 3.3× (better) |
| P/B | 31.8× | 3.4× (better) |
| FCF yield | −0.53% (better) | −2.9% |
| Fair value | – | $32.29 |
| Margin of safety | – | 13.9% |
| Growth | ||
| Revenue growth (TTM) | 50.1% (better) | 21.0% |
| Revenue growth, 5Y average | 23.0% | – |
| Profitability | ||
| Gross margin | 75.6% | 98.9% (better) |
| Operating margin | −12.2% | −5.2% (better) |
| Net margin | −20.7% | −4.2% (better) |
| FCF margin | −7.8% (better) | −9.6% |
| Return on equity | −39.6% | −4.5% (better) |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | −3.3× | −1.8× (better) |
| Current ratio | 4.79 (better) | 4.47 |
| Altman Z-score | 3.37 (better) | 1.40 |
| Piotroski F-score | 5 (better) | 3 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 97.6% | 102% |
| Held by insiders | 22.7% | 15.5% |
| Insider net buying, 12 months | −$118M | −$1.9M (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 9.3% | – |
Go deeper
- ADPT stock overview
- ADPT income statement
- ADPT valuation and score
- IMCR stock overview
- IMCR income statement
- IMCR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.